Characteristics of the studies, pharmacokinetics and dose recommendations of isolated studies on cefotaxime
| Study | n | PNA | Weight | Study design | Group | Model | Modality | Administered dose | Vd | CL | t1/2 (hours) | Recommended dose |
| Ahsman et al,26 the Netherlands | 37 | 3.3 (0.67–199) | 3.5 (2.0–6.2) | P 1 group | Neonates | 1-compartment with NONMEM | VV–VA | 50 mg/kg every 12 hours (PNA <1 week) 50 mg/kg every 8 hours (1<PNA<4 weeks) 37.5 mg/kg every 6 hours (PNA >4 weeks) | ECMO vs non-ECMO: 1.82 L vs 0.68–1.14 L ↑59.6%–167.6% | ECMO vs non-ECMO: 0.36 L/hour vs 0.20–0.55 L/hour ↔ | 3.5 hours | The standard cefotaxime dose regimen provides a sufficiently high t>MIC in infants undergoing ECMO. |
Boldfaced fonts represent comparisons with controls within the same study. In other studies, they represent comparisons with non-ECMO neonates from a different published study.
CL, clearance; ECMO, extracorporeal membrane oxygenation; MIC, minimum inhibitor concentration; NONMEM, non-linear mixed-effects modelling; P, prospective; PNA, postnatal age; t1/2, elimination half-life; VA, veno-arterial; Vd, volume of distribution; VV, veno-venous.